Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
Massimino M, Consoli ML, Mesuraca M, Stagno F, Tirrò E, Stella S, Pennisi MS, Romano C, Buffa P, Bond HM, Morrone G, Sciacca L, Di Raimondo F, Manzella L, Vigneri P. Massimino M, et al. Among authors: vigneri p. Carcinogenesis. 2014 May;35(5):1132-43. doi: 10.1093/carcin/bgu013. Epub 2014 Jan 20. Carcinogenesis. 2014. PMID: 24445143
BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.
Aloisi A, Di Gregorio S, Stagno F, Guglielmo P, Mannino F, Sormani MP, Bruzzi P, Gambacorti-Passerini C, Saglio G, Venuta S, Giustolisi R, Messina A, Vigneri P. Aloisi A, et al. Among authors: vigneri p. Blood. 2006 Feb 15;107(4):1591-8. doi: 10.1182/blood-2005-05-2123. Epub 2005 Oct 25. Blood. 2006. PMID: 16249386 Free article.
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.
Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, Van Etten RA, Donato N, Hunter A, Dinsdale D, Tirrò E, Vigneri P, Nicotera P, Dyer MJ, Holyoake T, Salomoni P, Calabretta B. Bellodi C, et al. Among authors: vigneri p. J Clin Invest. 2009 May;119(5):1109-23. doi: 10.1172/JCI35660. Epub 2009 Apr 13. J Clin Invest. 2009. PMID: 19363292 Free PMC article.
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.
Stagno F, Vigneri P, Del Fabro V, Stella S, Massimino M, Berretta S, Cupri A, Consoli C, Messina L, Tirrò E, Messina A, Di Raimondo F. Stagno F, et al. Among authors: vigneri p. Leuk Res. 2009 Sep;33(9):e157-8. doi: 10.1016/j.leukres.2009.03.040. Epub 2009 Apr 29. Leuk Res. 2009. PMID: 19406471 No abstract available.
Diabetes and cancer.
Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Vigneri P, et al. Among authors: vigneri r. Endocr Relat Cancer. 2009 Dec;16(4):1103-23. doi: 10.1677/ERC-09-0087. Epub 2009 Jul 20. Endocr Relat Cancer. 2009. PMID: 19620249 Review.
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias.
Stagno F, Vigneri P, Del Fabro V, Stella S, Restuccia N, Giallongo C, Massimino M, Berretta S, Pennisi MS, Tibullo D, Tirrò E, Buscarino C, Messina A, Di Raimondo F. Stagno F, et al. Among authors: vigneri p. Acta Oncol. 2010;49(1):109-10. doi: 10.3109/02841860903302913. Acta Oncol. 2010. PMID: 19842797 No abstract available.
177 results